Meisel A D, Bush M, Ginzler E, Diamond H S
State University of New York, Downstate Medical Center, Brooklyn 11203.
J Immunopharmacol. 1979;1(4):483-95. doi: 10.3109/08923977909040547.
Frentizole is a new immunoregulatory agent developed as an alternative to cytotoxic agents. In human lymphocytes, Frentizole inhibits the response to various phytomitogens without decreasing cell viability. Frentizole (500 ng/ml) inhibited thymidine incorporation into DNA most effectively when added to lymphocyte cultures at the same time as the addition of the mitogen. Frentizole (500 ng/ml) markedly inhibited the response to Con A (% inhibition, corporation was dose dependent with 125 ng/ml of Frentizole sufficient to inhibit significantly the response of all three mitogens. Frentizole (62.5 ng/ml) maximally inhibited uridine incorporation, and inhibition of uridine incorporation was independent of the phytomitogen employed. Increasing concentrations of Frentizole were found to have no effect on thymidine or uridine incorporation into unstimulated normal lymphocytes.
氟仑替唑是一种新开发的免疫调节药物,可作为细胞毒性药物的替代品。在人淋巴细胞中,氟仑替唑可抑制对各种植物凝集素的反应,而不降低细胞活力。当与促细胞分裂剂同时添加到淋巴细胞培养物中时,氟仑替唑(500 ng/ml)最有效地抑制了胸腺嘧啶核苷掺入DNA。氟仑替唑(500 ng/ml)显著抑制对刀豆蛋白A的反应(抑制百分比,掺入呈剂量依赖性,125 ng/ml的氟仑替唑足以显著抑制所有三种促细胞分裂剂的反应。氟仑替唑(62.5 ng/ml)最大程度地抑制尿苷掺入,且尿苷掺入的抑制与所用植物凝集素无关。发现氟仑替唑浓度增加对未刺激的正常淋巴细胞中胸腺嘧啶核苷或尿苷的掺入没有影响。